Drug Trial Radar · NCT00052455
Temozolomide Compared to Procarbazine, Lomustine, and Vincristine in Treating Patients With Recurrent Malignant Glioma
Last checked: Nov 20, 2026Latest source record: Dec 18, 2013 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
500
Planned (sponsor's estimate)
Start
Oct 2002
Primary completion
Not stated
Study completion Sep 2010
Sponsor
- Lead sponsor
- Institute of Cancer Research, United KingdomAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Jan 27, 2003
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells. It is not yet known which regimen of chemotherapy is more effective in treating recurrent malignant glioma. PURPOSE: Randomized phase III trial to compare the effectiveness of temozolomide alone to that of procarbazine, lomustine, and vincristine in treating patients who have recurrent malignant glioma.
Conditions
- Brain and Central Nervous System Tumors
Interventions
lomustineDrug
procarbazine hydrochlorideDrug
temozolomideDrug
vincristine sulfateDrug
Primary outcomes
What the sponsor says the trial is designed to measure.
- Overall survival
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Medical Research Council Clinical Trials Unit
London, England, United Kingdom
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.